The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Improving CAR T-cell therapy for myeloma
Lekha Mikkilineni, MD, National Institutes of Health, Bethesda, MD, shares insight into the status of the chimeric antigen receptor (CAR) T-cell therapy field in multiple myeloma. She emphasizes the significant benefit that the introduction of CAR T-cell therapy has had, enabling deep and durable responses to be seen in relapsed/refractory patients, as well as the quality of life benefits that come from having a single infusion treatment. However, relapses still occur, particularly in patients with extramedullary disease or treatment induced BCMA-negative disease. Finding alternative targets for these patient subgroups needs to be a focus of future research. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
